Latest Breaking News On - Dupilumab development program - Page 6 : comparemela.com

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France generalRegeneron velocimmuneGeorged yancopoulosNaimish patelRegeneron velocimmune technologyDrug administrationDupilumab development programRegeneron pharmaceuticals incExchange commissionHead of global developmentRegeneron genetics centerPriority reviewChief scientific officerPediatric eoeSymptom questionnaire caregiverGlobal development

Sanofi - Aventis Groupe: Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

Sanofi - Aventis Groupe: Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

France generalStefan klotterGeorged yancopoulosVesna tosicNaimish patelRegeneron pharmaceuticals incDrug administrationClinical research programHead of global developmentDupilumab development programBoard coTrial programExchange commissionRegeneron genetics centerGlobal developmentBreakthrough therapy

Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease

NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with evidence.

United statesFrance generalNaimish patelEva schaefer jansenNathalie phamSharon chenFelix lauscherCorentine driancourtEvan berlandVesna tosicArnaud delepineRegeneron velocimmuneGeorged yancopoulosSally bainBoard coHead of global development

Press Release: Dupixent® (dupilumab) Phase 3 Results show

Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE) .

France generalVesna tosicEvan berlandMirna chehadeEva schaefer jansenSally bainTarik elgoutniCorentine driancourtFelix lauscherNathalie phamSharon chenDupilumab development programAmerican college of gastroenterologyIcahn school of medicineExchange commissionDrug administration

Dupixent® (dupilumab) Phase 3 Results Show Sustained

Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose.

France generalNew yorkUnited statesMirna chehadeRegeneron velocimmuneGeorged yancopoulosExchange commissionIcahn school of medicine at mount sinaiRegeneron genetics centerRegeneron velocimmune technologyAmerican college of gastroenterologyDupilumab development programRegeneron pharmaceuticals incMount sinai centerDrug administrationPriority review